Zymfentra is a subcutaneous infliximab product used to treat ulcerative colitis and Crohn’s disease. It has a price of $6,181.08 for two shots over four weeks.
Formulary Watch
Latest News
All News
Advertisement
The FDA has given mirdametinib a Prescription Drug User Fee Act (PDUFA) action date of Feb. 28, 2025, to treat patients with neurofibromatosis type 1 with tumors that grow along the peripheral nerve.
Through the PfizerForAll platform, patients can connect with a healthcare professional, find and book vaccines, order tests, and find medication savings information.
The monthly price of the 2.5 mg Zepbound single-dose vial is $399 and the 5 mg dose is $549, which Lilly officials said is in line with the savings program for without insurance.
Beginning in 2025, Express Scripts will favor biosimilars of Humira, including its own private-label version.
The updated vaccines include the KP.2 strain of the Omicron variant, which is believed to be contributing to the increases in COVID-19 infections this summer.
Avalere’s Kylie Stengel talks about the regional shifts in formularies and utilization management in Medicare Part D prescription drug plans.
The FDA has assigned a Prescription Drug User Fee Act of Dec. 20, 2024, for Zynquista (sotagliflozin) to control glycemic levels in adults with type 1 diabetes and chronic kidney disease.
The FDA identified at a third party fill and finish manufacturer. The issues have been resolved, and reinspection is expected in the next few months.
This therapy is a first-in-class treatment for chronic graft-versus-host disease, which develops in roughly 42% of those who receive a stem cell of bone marrow transplant.
Advertisement
Livdelz is an oral therapy to treat patients with primary biliary cholangitis, a progressive autoimmune disease. It is expected to be available in pharmacies next week.
This first-in-class treatment targets multiple disease mechanisms such as itch and inflammation associated with this condition.
Prademagene zamikeracel is a cell therapy in development to treat patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder.
Zymfentra launched in March 2024 as the first subcutaneous formulation of infliximab for patients with ulcerative colitis and Crohn’s disease. It has a list price of $6,181.08 for two shots over four weeks.
No information, however, is available about which insurance plans are providing coverage of Anktiva or what the utilization management requirements are.
Enzeevu is biosimilar to Eylea (aflibercept), which was FDA-approved in 2019.
In June, an FDA advisory committee voted against approval of midomafetamine capsules (MDMA) for adults living with posttraumatic stress disorder (PTSD).
Neffy is the first epinephrine product that does not need to be administered by injection and the first new epinephrine delivery method in 35 years. It will be available at a starting price of $25.
New analysis shows that differences in the methods used to set drug payment amounts under Part B versus under Part D result in different payment amounts for the same drugs.
Crexont kept symptoms at bay for an extra 30 minutes a day when compared with other Parkinson’s drugs.
In a recent survey, payers said their priorities include addressing the impacts of Medicare’s Drug Price Negotiation Program and the Part D redesign.
SelfJect is priced at parity with the Acthar Gel multi-dose vial and syringe.
Cigna officials cite significant growth in Evernorth Health Services and Express Scripts for the increase in revenue.
CVS Caremark is requiring step therapy through a generic prescription proton pump inhibitor before providing coverage.
Zunveyl, a prodrug of galantamine that addresses the gastrointestinal side effects, will be available in the first quarter of 2025.
Higher costs per claim, coupled with an increased number of patients using specialty drugs, has contributed to higher spend.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New hypertension drugs show no advantage over older generics
2
Physicians may be the key for affordable healthcare
3
Inaccurate data in provider directories is costing health plans. Why a national provider diectory and data science are the fix
4
Noninvasive imaging of basal cell carcinoma: Examining the choices
5